A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds

Inclusion Criteria:

• 7~17 years old at the time of screening

• Volunteers and their legal guardians or delegates have given informed consent, havevoluntarily signed an informed consent form, are able and willing to comply with therequirements of the clinical trial protocol, and are able to complete 180 days ofstudy follow-up

• Willingness to discuss medical history with the investigator or physician and toallow access to all medical records related to this trial

Exclusion Criteria:

• Fever on the day of vaccination, axillary temperature >37.0°C

• Have a moderate or severe acute illness/infection

• Positive urine pregnancy test for females of childbearing age, or plan to becomepregnant within 30 days after vaccination

• Current meningitis or history of meningitis

• Allergy to certain components or excipients of the drugs used in this clinical trial (mainly including: group A meningococcal podoplanoside, group C meningococcalpodoplanoside, group Y meningococcal podoplanoside, group W135 meningococcalpodoplanoside, sucrose, mannitol, sodium chloride, dipotassium hydrogen phosphatetrihydrate, potassium dihydrogen phosphate)

• History of epilepsy, convulsions or seizures or history or family history ofpsychiatric disorders

• Previous severe allergic reactions due to drugs or vaccines

• Bleeding constitution or condition associated with prolonged bleeding, which in theopinion of the investigator makes intramuscular injection contraindicated

• Any meningococcal vaccine in the last 1 year

• Any other vaccine within 14 days

• Participation in other studies involving interventional studies within 28 days (<28days) prior to study entry and/or during study participation

• Other conditions that, in the judgment of the investigator, make participation inthis clinical trial unsuitable